A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
NCT03472053
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Cancer Stage IIIB
Interventions
DRUG:
BIO-11006 plus standard of care
DRUG:
Standard of Care
Sponsor
BioMarck Pharmaceuticals, Ltd.